Evotec IPO
Evotec is a German drug discovery and development company that provides integrated solutions for pharmaceutical and biotechnology companies. The company operates discovery platforms and maintains a portfolio of partnered programs and proprietary pipeline assets, making it a key player in the outsourced drug discovery market.
Key Facts
| Industry | Biotechnology Services |
| Founded | 1993 |
| Headquarters | Hamburg, Germany |
| Employees | ~4,500 |
| Website | evotec.com |
| Funding | Public company (Frankfurt: EVT, NASDAQ: EVO) |
About Evotec
Evotec is a global drug discovery and development company that provides integrated solutions from target identification through clinical development for pharmaceutical and biotechnology companies. The company operates a unique business model combining fee-for-service research with shared-risk partnerships, where Evotec takes equity stakes in programs and receives milestone payments and royalties on successful drugs.
The company has built one of the industry's most comprehensive drug discovery platforms, including expertise in small molecules, biologics, and cell therapies across multiple therapeutic areas. Evotec has contributed to the discovery and development of more than 130 partnered programs currently in clinical development, with several approved drugs including Otezla (psoriasis) and Abraxane (cancer). Their EVT Innovate division focuses on building a portfolio of co-owned programs with biotech partners, creating a pipeline of potential blockbuster drugs.
IPO Status
Evotec has been publicly traded for many years and is listed on the Frankfurt Stock Exchange under the ticker EVT. The company also trades on NASDAQ as an ADR under the ticker EVOTF, providing access to U.S. investors. The company has built a strong reputation in the contract research organization (CRO) space and has expanded through strategic acquisitions and partnerships. Evotec's business model combines fee-for-service drug discovery with risk-sharing partnerships, and the company has demonstrated consistent growth in recent years as pharmaceutical companies increasingly outsource early-stage research activities.
Competitors
Frequently Asked Questions
Does Evotec have a stock?
Yes, Evotec is already publicly traded and has been for many years. The company is listed on the Frankfurt Stock Exchange and also trades as an ADR on NASDAQ.
When is the Evotec IPO date?
Evotec is already publicly traded and completed its IPO years ago. There is no upcoming IPO as the company has been public for an extended period.
How can I buy Evotec stock?
You can buy Evotec stock through brokerages that offer international trading or through its ADR listing on NASDAQ under ticker EVOTF. The primary listing is on the Frankfurt Stock Exchange under ticker EVT.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts